Company patents
Kyowa Kirin Co., Ltd.
Kyowa Kirin Co., Ltd. demonstrates a strong, albeit fluctuating, focus on core pharma_biotech areas, with Peptides & Proteins (67.3% of portfolio) and Pharmaceutical Preparations (60.0%) being dominant. While patenting in Pharmaceutical Preparations saw a significant surge in 2024 (+116.7% YoY), the company's interest in Heterocyclic Compounds (Pharma) appears to be a shifting priority, with a -100.0% decline in 2025, and only 1 patent so far in 2026.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
55 US filings (since 2023) · 6 categories · 13 themes
Design and modification of antibodies or antibody-derived fragments for targeted therapeutic intervention, including bispecific formats, Fc region modifications, and activatable constructs.
Design and engineering of proteins or peptides to directly modulate immune responses, including enhancing antigen presentation, suppressing inflammation, or activating specific immune cell types.
Methods and compositions for identifying, quantifying, or characterizing specific biological molecules (e.g., nucleic acids, proteins, metabolites, antibodies) or microbial species, often for diagnostic, prognostic, or quality control applications.
Development of small molecules, often bifunctional (e.g., PROTACs) or molecular glues, that induce the ubiquitin-proteasome system or autophagy to selectively degrade specific disease-causing proteins.
Development and application of therapeutic proteins or peptides produced through recombinant DNA technology, including fusion proteins and modified growth factors.
Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.
Therapeutic strategies employing nucleic acids (DNA, RNA, oligonucleotides) to modulate gene expression, deliver genetic material, or interfere with disease-causing pathways. Includes gene therapy using viral vectors.
Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.
Therapeutic interventions that target immune checkpoint pathways to either enhance or suppress immune responses, often used in cancer immunotherapy or autoimmune diseases.
Methods and systems for the efficient and scalable production, purification, and formulation of proteins and peptides, including fermentation, chromatography, and cell-based expression systems.
Delivery systems specifically engineered to administer advanced drug formulations (e.g., microparticles, biologics, extended-release systems) to achieve precise targeting, controlled release kinetics, or enhanced therapeutic efficacy within the body.
Processes and methodologies for the efficient and scalable preparation of complex heterocyclic compounds and their precursors, including specific reaction conditions, purification techniques, and intermediate compounds.
Development of materials with tailored porosity, surface chemistry, or structure, such as metal-organic frameworks (MOFs), zeolites, or superficially porous particles, for selective adsorption, ion exchange, or chromatographic separations.
Patents
Showing 1-10 of 100